Jung Sung Woo, Thamphiwatana Soracha, Zhang Liangfang, Obonyo Marygorret
Department of Medicine, University of California San Diego, La Jolla, United States of America; Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.
Department of NanoEngineering, University of California San Diego, La Jolla, United States of America.
PLoS One. 2015 Mar 20;10(3):e0116519. doi: 10.1371/journal.pone.0116519. eCollection 2015.
Helicobacter pylori infects approximately half of the world population and is a major cause of gastritis, peptic ulcer, and gastric cancer. Moreover, this bacterium has quickly developed resistance to all major antibiotics. Recently, we developed a novel liposomal linolenic acid (LipoLLA) formulation, which showed potent bactericidal activity against several clinical isolated antibiotic-resistant strains of H. pylori including both the spiral and coccoid form. In addition, LipoLLA had superior in vivo efficacy compared to the standard triple therapy. Our data showed that LipoLLA associated with H. pylori cell membrane. Therefore, in this study, we investigated the possible antibacterial mechanism of LipoLLA against H. pylori. The antibacterial activity of LipoLLA (C18:3) was compared to that of liposomal stearic acid (LipoSA, C18:0) and oleic acid (LipoOA, C18:1). LipoLLA showed the most potent bactericidal effect and completely killed H. pylori within 5 min. The permeability of the outer membrane of H. pylori increased when treated with LipoOA and LipoLLA. Moreover, by detecting released adenosine triphosphate (ATP) from bacteria, we found that bacterial plasma membrane of H. pylori treated with LipoLLA exhibited significantly higher permeability than those treated with LipoOA, resulting in bacteria cell death. Furthermore, LipoLLA caused structural changes in the bacterial membrane within 5 min affecting membrane integrity and leading to leakage of cytoplasmic contents, observed by both transmission electron microscopy (TEM) and scanning electron microscopy (SEM). Our findings showing rapid bactericidal effect of LipoLLA suggest it is a very promising new, effective anti-H. pylori agent.
幽门螺杆菌感染了全球约一半的人口,是胃炎、消化性溃疡和胃癌的主要病因。此外,这种细菌已迅速对所有主要抗生素产生耐药性。最近,我们开发了一种新型的脂质体亚麻酸(LipoLLA)制剂,它对几种临床分离的幽门螺杆菌抗生素耐药菌株(包括螺旋形和球形)显示出强大的杀菌活性。此外,与标准三联疗法相比,LipoLLA在体内具有更高的疗效。我们的数据表明LipoLLA与幽门螺杆菌细胞膜相关。因此,在本研究中,我们研究了LipoLLA对幽门螺杆菌可能的抗菌机制。将LipoLLA(C18:3)的抗菌活性与脂质体硬脂酸(LipoSA,C18:0)和油酸(LipoOA,C18:1)的抗菌活性进行了比较。LipoLLA显示出最强大的杀菌效果,并在5分钟内完全杀死了幽门螺杆菌。用LipoOA和LipoLLA处理后,幽门螺杆菌外膜的通透性增加。此外,通过检测细菌释放的三磷酸腺苷(ATP),我们发现用LipoLLA处理的幽门螺杆菌细菌质膜的通透性明显高于用LipoOA处理的,导致细菌细胞死亡。此外,通过透射电子显微镜(TEM)和扫描电子显微镜(SEM)观察发现,LipoLLA在5分钟内导致细菌膜结构发生变化,影响膜的完整性并导致细胞质内容物泄漏。我们的研究结果表明LipoLLA具有快速杀菌作用,表明它是一种非常有前途的新型有效抗幽门螺杆菌药物。